High Dose Trial in COPD

Completed · Phase 2

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

The primary objective of this study was to compare the efficacy and safety of 200 μg and 400 μg of BEA 2180 BR to tiotropium 5 μg and placebo when each was delivered by the Respimat® Inhaler once daily for four weeks in patients with COPD.

Key facts

Study ID

NCT00128440

Run by

Boehringer Ingelheim

People needed

78

Starts

2005-08-01

Last updated by the study team

2013-10-29

Who can join

Age: 40 and older, up to 84. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Boehringer Ingelheim Investigational Site — Lakewood, California, United States
• Boehringer Ingelheim Investigational Site — Wheat Ridge, Colorado, United States
• Boehringer Ingelheim Investigational Site — Pembroke Farms, Florida, United States
• Boehringer Ingelheim Investigational Site — Coeur d'Alene, Idaho, United States
• Boehringer Ingelheim Investigational Site — Reno, Nevada, United States
• Boehringer Ingelheim Investigational Site — Larchmont, New York, United States
• Boehringer Ingelheim Investigational Site — Winston-Salem, North Carolina, United States
• Boehringer Ingelheim Investigational Site — Charleston, South Carolina, United States
• Boehringer Ingelheim Investigational Site — Harker Heights, Texas, United States
• Boehringer Ingelheim Investigational Site — Houston, Texas, United States
• Boehringer Ingelheim Investigational Site — San Antonio, Texas, United States
• Boehringer Ingelheim Investigational Site — Richmond, Virginia, United States
• Boehringer Ingelheim Investigational Site — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.